Product
Branebrutinib
Aliases
BMS-986195
2 clinical trials
3 indications
Indication
Healthy Control ParticipantsIndication
DermatitisIndication
AtopicClinical trial
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Branebrutinib in a Tablet Formulation Relative to Branebrutinib (RBA) in a Capsule Formulation Including the Effect of Food (Low-fat/Low-calorie and a High-fat/High-calorie) on the Bioavailability of Branebrutinib From a Tablet Formulation and a Double-blind Study to Evaluate the Safety and Pharmacokinetics of Branebrutinib From a Tablet Formulation in a Multiple-dose Arm in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-08-22